An interventional study of Cervical Foley combined with Misoprostol and Dinoprostone 10mg insert OR in Labor, Induced and Cervical Ripening, sponsored by Centro Hospitalar De São João, E.P.E.. Completed at 1 site in Portugal. Open to female participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-01-23.
Sponsored by Centro Hospitalar De São João, E.P.E. · Not applicable, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Labor induction is a common pregnancy procedure worldwide. Both mechanical and pharmacologic agents are used for induction of labor. These agents reduce the incidence of cesarean delivery in women undergoing induction.
Opposite to old studies of cervical ripening, some recent studies have shown promise in reducing labor time and risk of cesarean delivery with combination methods. The effectiveness of this procedure is of major clinical importance and has a large impact in our quotidian practice.
The objective is to compare the effectiveness of a combined new method to current guidelines of our department
We designed a randomized trial that will compare two groups: misoprostol-cervical Foley simultaneously and the current department guidelines (misoprostol alone/dinoprostone alone).
Inclusion criteria: full-term (≥ 37 weeks of gestation), singleton, vertex-
Centro Hospitalar De São João, E.P.E. is the lead sponsor of 12 studies on the registry; 2 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
* 25 micrograms misoprostol vaginal applied placed along with cervical Foley (team will repeat misoprostol application each 4 hours till 6 doses of misoprostol) * After 4 hours of last misoprostol initiate oxytocin. * Cervical Foley will be removed after 12h of placement or when fails out.
Combination Product: Cervical Foley combined with Misoprostol
* Following current department guidelines, as usual, with the method considered more suitable. * If they opted for vaginal misoprostol, team will insert 25micrograms, repeat application 4/4h, until 150micrograms, after last misoprostol, wait 4 hours before initiating oxytocin. * If option is vaginal dinoprostone the insert of 10mg is removed after 24h in place.
Drug: Dinoprostone 10mg insert OR · Drug: Misoprostol
Placement of cervical Foley catheter along with application of vaginal misoprostol 25ug that will be repeated 4/4h until 150ug
Application for 24h of Dinoprostone 10mg insert
Application of vaginal misoprostol 25ug 4/4h until 150ug
Time to delivery
Time to delivery
Time frame: 3 days
cesarean delivery rate
cesarean delivery rate
Time frame: 3 days
time to active labor
defined as dilation of 6 cm or greater
Time frame: 3 days
rate of delivery within 12 hours
rate of delivery within 12 hours
Time frame: 12 hours
rate of delivery within 24 hours
rate of delivery within 24 hours
Time frame: 24 hours
mean of maternal length of stay
induction to discharge
Time frame: average 3 days
indication for cesarean delivery
indication for cesarean delivery
Time frame: 3 days
composite maternal morbidity outcome
third- or fourth-degree perineal laceration, blood transfusion, chorioamnionitis, endometritis, wound infection, venous thromboembolism, hysterectomy, intensive care unit admission or death.
Time frame: 6 weeks
composite of neonatal morbidities
SDR, neonatal sepsis, blood transfusion, encephalopathy hypoxic-ischemic, intraventricular hemorrhage of grade III/IV
Time frame: 30 days
Plan to share: Yes — Study Protocol, Informed Consent Form, Statistical Analysis Plan
Supporting information: Study protocol, Statistical analysis plan, Informed consent form
Time frame: no ending
Access criteria: Researchers who provide a methodologically sound proposal.
No publications or documents are linked to this record.
Ran from Feb 2018 to primary completion in Jan 2020, 23 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Centro Hospitalar De São João, E.P.E.